VivoSeq
Other

Antibody

0

Pipeline Programs↗

9

Active Trials↗

17

Companies Involved↗

Antibody is an early-stage landscape with 0 programs across 17 companies. The most active players are GSK, Amgen, Sanofi.

Intelligence

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

88/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

GSK logo

GSK

0 programs

PreclinicalAmgen logo

Amgen

0 programs

PreclinicalSanofi logo

Sanofi

0 programs

PreclinicalNovartis logo

Novartis

0 programs

PreclinicalNovo Nordisk logo

Novo Nordisk

0 programs

PreclinicalS

Staten Biotechnology BV

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

63

clinical trials

Completed46 · 73%
Recruiting4 · 6%
Terminated4 · 6%
Not yet recruiting3 · 5%
Active, not recruiting2 · 3%
Withdrawn2 · 3%
Other2 · 3%

Clinical Trials

Trial Activity

63 trials

HEAT Trial (HER2 Antibody Therapy With Lutetium-177)
Recruiting·RRadiopharm Theranostics, Ltd·Phase 1·NCT06824155·30 enrolled
Effect of Belimumab on Antibody Titers in Primary APS Patients
Recruiting·RRuijin Hospital·Phase 2·NCT06747312·20 enrolled
A First-in-human Study of the Safety of an Immunosuppressive Antibody (IMP761) in Healthy Volunteers
Recruiting·—·Phase 1·NCT06637865·79 enrolled
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
Recruiting·—·Phase 2·NCT06263543·75 enrolled
Plateau Antibody Levels of a Recombinant (E.Coli) HPV Nonavalent Vaccine Versus Gardasil®9 in Young Women
Active, not recruiting·XXiamen University·N/A·NCT06197802·392 enrolled
A Study to Assess Safety, Pharmacokinetics Anti-Drug Antibody and Anti-RSV Antibody After 2 Doses of Nirsevimab
Active, not recruiting·AstraZeneca logoAstraZeneca·Phase 3·NCT06042049·33 enrolled
Longitudinal Evaluation of Antibody Kinetics of Vaccinated Patients With Non-mandatory Vaccine Following Administration of a Non-public Marketed Vaccine in the General Population, Real-life Study
Not yet recruiting·CCerbaXpert·N/A·NCT06373510·10,000 enrolled
The Phase I Study of SIG001 Antibody on Cancer Therapy.
Not yet recruiting·PPeking University·Phase 1·NCT07486700·66 enrolled
Safety and Efficacy of the Bispecific T-Cell Engager (BiTE) in Kidney Transplant Recipients With Chronic Active Antibody-Mediated Rejection
Not yet recruiting·WWest China Hospital·Approved·NCT07689578·50 enrolled
Antibody Persistence and Booster Dose Response in Subjects Who Received Menactra® Three Years Earlier in Study MTA26
Completed·Sanofi logoSanofi·Phase 2·NCT00700713·181 enrolled
First-In-Human Study to Evaluate Safety And Pharmacokinetics of Single Escalating Doses of BCD-147 (Bispecific Anti-HER2/HER2 Antibody) in Healthy Subjects
Completed·BBiocad·Phase 1·NCT03912441·15 enrolled
A Single and Multiple Dosing Study Targeting Biparatopic Antibody CD38 in Healthy Volunteers
Completed·TTeneoFour Inc.·Phase 1·NCT05215912·31 enrolled
Study of JYB1904 (an Anti-immunoglobulin E Antibody) in Healthy Chinese Subjects
Completed·JJemincare·Phase 1·NCT05449535·56 enrolled
Duration of IPV Priming and Antibody Decay
Completed·Centers for Disease Control and Prevention·Phase 4·NCT03202719·1,645 enrolled
Safety Study With the Antibody, cG250, and Isotope, 124-Iodine, to Diagnose Patients With Renal Masses.
Completed·LLudwig Institute for Cancer Research·Phase 1·NCT00199888·26 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)